Published in Gene Therapy Weekly, September 21st, 2000
"Malignant glial brain tumors (MGT), i.e., glioblastomas, anaplastic astrocytomas, and malignant gliomas, remain a major therapeutic challenge in adults and children," stated Gilles Vassal and colleagues from several institutions in France, and Onyx Pharmaceuticals, California. "Since p53 gene is frequently mutated in these tumors, we evaluated the antitumor activity of ONYX-015, an E1B-55 kd gene deleted adenovirus that selectively replicates in and destroys tumor cells...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.